Table 5 Frequency and main characteristics of lymphoma subtypes in outpatient and inpatient cohorts according to referral sources
OPs (N = 1184) | IPs (N = 535) | |||||
|---|---|---|---|---|---|---|
PC (n = 894) | ED (n = 290) | P value | PC (n = 169) | ED (n = 366) | P value | |
Classical Hodgkin lymphoma, n (%) | 183 (20.5) | 33 (11.3) | <.001 | 41 (24.3) | 61 (16.7) | <.001 |
Large B-cell lymphoma, n (%) | 242 (27.1) | 127 (43.8) | <.001 | 54 (32.0) | 155 (42.3) | <.001 |
Follicular lymphoma, n (%) | 370 (41.4) | 69 (23.8) | <.001 | 50 (29.6) | 73 (19.9) | <.001 |
Nodal peripheral T-cell lymphoma, n (%) | 106 (11.9) | 54 (18.6) | <.001 | 24 (14.2) | 77 (21.0) | <.001 |
Age > 60 years, n (%) | 451 (50.4) | 160 (55.2) | <.001 | 123 (72.8) | 260 (71.0) | .108 |
ECOG performance score > 1, n (%) | 120 (13.4) | 53 (18.3) | <.001 | 36 (21.3) | 87 (23.8) | .089 |
B symptoms, n (%) | 244 (27.3) | 93 (32.1) | .001 | 61 (36.1) | 143 (39.1) | .052 |
Systemic symptoms, n (%) | 186 (20.8) | 72 (24.8) | .012 | 57 (33.7) | 134 (36.6) | .060 |
Pain symptoms, n (%) | 33 (3.7) | 10 (3.4) | .197 | 14 (8.3) | 32 (8.7) | .210 |
Serum LDH > UNL, n (%) | 287 (32.1) | 115 (39.7) | <.001 | 68 (40.2) | 172 (47.0) | <.001 |
Ann Arbor III/IV stage, n (%) | 520 (58.2) | 173 (59.7) | .103 | 108 (63.9) | 244 (66.7) | .066 |
High risk IPI score (LBCL), n (%) | 42 (17.4) | 22 (17.3) | .230 | 13 (24.1) | 36 (23.2) | .167 |
High risk IPI score (NPTCL), n (%) | 32 (30.2) | 15 (27.8) | .081 | 9 (37.5) | 29 (37.7) | .231 |
High risk FLIPI score, n (%) | 101 (27.3) | 20 (29.0) | .098 | 16 (32.0) | 23 (31.5) | .195 |
High risk IPS score, n (%) | 25 (13.7) | 5 (15.2) | .106 | 8 (19.5) | 12 (19.7) | .252 |